Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced its participation in two upcoming conferences in May:
- Mizuho Healthcare Corporate Access Day at the Omni Berkshire Place Hotel in New York on Tuesday, May 5. Company management will participate in 1x1 meetings.
- 2015 UBS Global Healthcare Conference at the Sheraton New York Times Square Hotel in New York on Monday, May 18 at 1:00 p.m. EST. A live webcast will be available by visiting the Investor Center of the Epizyme website at www.epizyme.com. An archived replay of the webcast will be available on the Company’s website for 30 days after the conference.
About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients.
Manisha Pai, 617-229-7560